Press Releases and Events
PRESS RELEASES
Press Release | November 28, 2022
Press Release | November 22, 2022
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
READ MORE
Press Release | November 14, 2022
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
READ MORE
Press Release | November 10, 2022
Crinetics Announces November 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | October 13, 2022
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
READ MORE
Press Release | October 10, 2022
Crinetics Announces October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | October 6, 2022
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
READ MORE
Press Release | October 3, 2022
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
READ MORE
Press Release | September 12, 2022
Crinetics Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | September 8, 2022
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
READ MORE
SIGN UP
WEBCAST
PRESENTATIONTransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
